Xphyto Therapeutics (XPHY.C) subsidiary Xphyto Laboratories added mescaline to its list of psychedelic medicine programs today, according to a press release. Earlier this month the company brought Applied Pharmaceutical…
Xphyto Therapeutics
Xphyto Therapeutics (XPHY.C) subsidiary Xphyto Therapeutics entered into an agreement with Applied Pharmaceutical Innovation for the synthesis of pharma-grade psychedelic compounds and development of standard operating procedures to attract…
Xphyto describes itself as “a bioscience accelerator” “targeting growth through commercialization of its product pipeline”….
In lieu of the American markets not opening today courtesy of the civic holiday, Xphyto Therapeutics (XPHY.C) has elected to provide a glimpse into their business strategy and milestones…
The notion of magic mushroom market offering after the legalization of cannabis has been floated time and again since long before cannabis legalization was even on the table. It…
On Thursday, December 17th, 2020 the Virtual Life Sciences Investor Forum (VLSIF) presents a six biotech companies….
A few states in our neighbour to the south decided to offer psilocybin based therapies during the most recent spate of elections, prompting more potential for companies like Xphyto…
Today’s federal election results could change the regulatory landscape in Oregon and Washington DC, as the residents of those states will vote to decide if psilocybin should be decriminalised….
Xphyto Therapeutics (XPHY.C) diagnostic partner, 3a-Diagnostics GmbH, is getting onboard with the latest rush to develop a COVID-19 diagnostic kit, using reverse transcription polymerase chain reaction (RT-PCR) technology, which…
Increased product efficacy and patient convenience is anticipated through faster onset of drug action, more predictable therapeutic activity and ease of use….